Search results for "Crohn’"

showing 2 items of 32 documents

Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of…

2019

Patrizia Alvisi,1 Serena Arrigo,2 Salvatore Cucchiara,3 Paolo Lionetti,4 Erasmo Miele,5 Claudio Romano,6 Alberto Ravelli,7 Daniela Knafelz,8 Stefano Martelossi,9 Graziella Guariso,10 Salvatore Accomando,11 Giovanna Zuin,12 Costantino De Giacomo,13 Lucio Balzani,14 Monia Gennari,15 Marina Aloi3 On behalf of the SIGENP IBD Working Group 1Pediatric Gastroenterology Unit, Pediatric Department, Maggiore Hospital, Bologna, Italy; 2Pediatric Gastroenterology and Endoscopy Unit, G Gaslini Children’s Hospital, Genoa, Italy; 3Pediatric Gastroenterology and Liver Unit, Sapienza University of Rome, Rome, Italy; 4Gastroenterology and Nutrition Unit, Meyer Children’s Hospital, Florenc…

medicine.medical_specialtyPopulationadalimumab efficacy03 medical and health sciences0302 clinical medicineadalimumab efficacy; adalimumab safety; infliximab failure; pediatric crohn’s diseaseRheumatologyInternal medicinemedicineAdalimumabinfliximab failureImmunology and AllergyTargets and Therapy [Biologics]Pharmacology (medical)Adverse effecteducationPediatric gastroenterologyOriginal ResearchCrohn's diseaseeducation.field_of_studybusiness.industryAdalimumab efficacy; Adalimumab safety; Infliximab failure; Pediatric Crohn’s disease; Immunology and Allergy; Rheumatology; Oncology; Gastroenterology; Pharmacology (medical)Gastroenterologyadalimumab safetyHepatologymedicine.diseaseInfliximabOncology030220 oncology & carcinogenesisCohortpediatric Crohn’s disease030211 gastroenterology & hepatologybusinessmedicine.drugBiologics : Targets & Therapy
researchProduct

Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease

2018

Objectives Vedolizumab (VDZ) blocks α4β7 integrin and is licenced for the treatment of IBD. It has been associated with mild SpA-related features, including sacroiliitis and synovitis. Herein we report a series of cases demonstrating the emergence of severe SpA-associated enthesitis/osteitis following successful IBD therapy with VDZ. Methods We evaluated 11 VDZ-treated patients with IBD across seven centres who developed severe active SpA and/or enthesopathy, with the aim of characterizing the VDZ-associated SpA or entheseal flares. Imaging features demonstrating particularly severe disease were recorded. Results De novo SpA developed in 9 of 11 patients and flare of known SpA in 2 patients…

musculoskeletal diseasesvedolizumabmedicine.medical_specialtySpondyloarthropathyenthesitimucosal vascular addressin cell adhesion molecule-1 (MADCAM-1)Vedolizumabulcerative coliti03 medical and health sciences0302 clinical medicineRheumatologyInternal medicinemedicinePharmacology (medical)030212 general & internal medicinespondyloarthritiα4β7 integrin030203 arthritis & rheumatologyCrohn's diseaseAnkylosing spondylitisbusiness.industryEnthesopathySacroiliitisEnthesitismedicine.diseaseankylosing spondylitispondylarthritiCrohn’Osteitismedicine.symptombusinessaxial SpAmedicine.drug
researchProduct